BR0317222A - Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas - Google Patents
Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetasInfo
- Publication number
- BR0317222A BR0317222A BR0317222-8A BR0317222A BR0317222A BR 0317222 A BR0317222 A BR 0317222A BR 0317222 A BR0317222 A BR 0317222A BR 0317222 A BR0317222 A BR 0317222A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- platelet
- adenisine
- aminocarbonyl
- receptor antagonists
- Prior art date
Links
- 239000001177 diphosphate Substances 0.000 title 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 title 1
- 235000011180 diphosphates Nutrition 0.000 title 1
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
"COMPOSTOS DE 2-AMINOCARBONIL-QUINOLINA COMO ANTAGONISTAS DOS RECEPTORES DE DIFOSFATO DE ADENOSINA DE PLAQUETAS". A presente invenção refere-se a compostos da fórmula I, em que m, n, R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬ e R¬ 6¬ são descritos aqui, são úteis como inibidores do difosfato de adenosina das plaquetas. Composições farmacêuticas contendo estes compostos, processos de utilização destes compostos como agentes antitrombóticos e processos para a síntese destes compostos também são descritos aqui.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43279202P | 2002-12-11 | 2002-12-11 | |
| PCT/US2003/039079 WO2004052366A1 (en) | 2002-12-11 | 2003-12-09 | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317222A true BR0317222A (pt) | 2005-11-01 |
Family
ID=32507994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317222-8A BR0317222A (pt) | 2002-12-11 | 2003-12-09 | Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7056923B2 (pt) |
| EP (1) | EP1578423B1 (pt) |
| JP (1) | JP4662777B2 (pt) |
| KR (1) | KR20050085580A (pt) |
| CN (1) | CN1747732A (pt) |
| AP (1) | AP2005003363A0 (pt) |
| AT (1) | ATE477800T1 (pt) |
| AU (1) | AU2003297763A1 (pt) |
| BR (1) | BR0317222A (pt) |
| CA (1) | CA2507657C (pt) |
| DE (1) | DE60333866D1 (pt) |
| EA (1) | EA200500899A1 (pt) |
| EC (1) | ECSP055912A (pt) |
| ES (1) | ES2348942T3 (pt) |
| MX (1) | MXPA05006302A (pt) |
| NO (1) | NO20053335L (pt) |
| NZ (1) | NZ540872A (pt) |
| OA (1) | OA12970A (pt) |
| PL (1) | PL377053A1 (pt) |
| RS (1) | RS20050450A (pt) |
| UA (1) | UA83648C2 (pt) |
| WO (1) | WO2004052366A1 (pt) |
| ZA (1) | ZA200505492B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| ATE469157T1 (de) * | 2003-10-21 | 2010-06-15 | Inspire Pharmaceuticals Inc | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| CA2619706A1 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity quinoline-based kinase ligands |
| DE102006020385A1 (de) * | 2006-04-28 | 2007-10-31 | Dade Behring Marburg Gmbh | Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen |
| AR063258A1 (es) | 2006-10-13 | 2009-01-14 | Actelion Pharmaceuticals Ltd | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| EP2148871A1 (en) * | 2007-04-23 | 2010-02-03 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| CA2690243A1 (en) | 2007-06-18 | 2008-12-24 | Sanofi-Aventis | Pyrrole derivatives as p2y12 antagonists |
| AR069494A1 (es) | 2007-11-29 | 2010-01-27 | Actelion Pharmaceuticals Ltd | Derivados de acidos fosfonicos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| SG175075A1 (en) * | 2009-04-08 | 2011-11-28 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adp receptor antagonists |
| MX2011010811A (es) | 2009-04-22 | 2011-10-28 | Actelion Pharmaceuticals Ltd | Derivados de tiazol y su uso como antagonistas del receptor p2y12. |
| CN102304108B (zh) * | 2011-06-28 | 2013-11-06 | 中国药科大学 | 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途 |
| CN104151235B (zh) * | 2014-08-07 | 2016-01-20 | 南阳师范学院 | 一种喹啉衍生物制备方法 |
| MY193080A (en) | 2016-09-22 | 2022-09-26 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| KR102510832B1 (ko) | 2017-03-15 | 2023-03-15 | 이도르시아 파마슈티컬스 리미티드 | P2y12 수용체 안타고니스트의 피하 투여 |
| CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
| CN112920181A (zh) * | 2021-01-29 | 2021-06-08 | 中国医科大学 | N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US60474A (en) * | 1866-12-18 | Pbtee chick | ||
| GB1334705A (en) | 1970-06-19 | 1973-10-24 | Ici Ltd | Pharmaceutical compositions containing kynurenic acid derivatives |
| US4258192A (en) * | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| JPH05503300A (ja) | 1990-11-15 | 1993-06-03 | ペンタファルム アクチェンゲゼルシャフト | メタ置換フェニルアラニン誘導体 |
| WO1994018185A1 (de) * | 1993-02-10 | 1994-08-18 | Pentapharm Ag | Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren |
| KR0173034B1 (ko) | 1995-04-28 | 1999-03-30 | 성재갑 | 선택적 트롬빈 억제제 |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
-
2003
- 2003-12-09 PL PL377053A patent/PL377053A1/pl not_active Application Discontinuation
- 2003-12-09 AU AU2003297763A patent/AU2003297763A1/en not_active Abandoned
- 2003-12-09 DE DE60333866T patent/DE60333866D1/de not_active Expired - Lifetime
- 2003-12-09 KR KR1020057010688A patent/KR20050085580A/ko not_active Application Discontinuation
- 2003-12-09 NZ NZ540872A patent/NZ540872A/en unknown
- 2003-12-09 AT AT03796831T patent/ATE477800T1/de not_active IP Right Cessation
- 2003-12-09 AP AP2005003363A patent/AP2005003363A0/xx unknown
- 2003-12-09 EA EA200500899A patent/EA200500899A1/ru unknown
- 2003-12-09 OA OA1200500175A patent/OA12970A/en unknown
- 2003-12-09 BR BR0317222-8A patent/BR0317222A/pt not_active IP Right Cessation
- 2003-12-09 ES ES03796831T patent/ES2348942T3/es not_active Expired - Lifetime
- 2003-12-09 US US10/731,815 patent/US7056923B2/en not_active Expired - Fee Related
- 2003-12-09 EP EP03796831A patent/EP1578423B1/en not_active Expired - Lifetime
- 2003-12-09 UA UAA200506729A patent/UA83648C2/ru unknown
- 2003-12-09 JP JP2004558607A patent/JP4662777B2/ja not_active Expired - Fee Related
- 2003-12-09 CA CA2507657A patent/CA2507657C/en not_active Expired - Fee Related
- 2003-12-09 WO PCT/US2003/039079 patent/WO2004052366A1/en active Application Filing
- 2003-12-09 RS YUP-2005/0450A patent/RS20050450A/sr unknown
- 2003-12-09 MX MXPA05006302A patent/MXPA05006302A/es active IP Right Grant
- 2003-12-09 CN CNA2003801096637A patent/CN1747732A/zh active Pending
-
2005
- 2005-07-08 NO NO20053335A patent/NO20053335L/no not_active Application Discontinuation
- 2005-07-11 EC EC2005005912A patent/ECSP055912A/es unknown
-
2006
- 2006-01-12 US US11/331,621 patent/US7084142B2/en not_active Expired - Fee Related
- 2006-01-17 ZA ZA200505492A patent/ZA200505492B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20053335D0 (no) | 2005-07-08 |
| WO2004052366A1 (en) | 2004-06-24 |
| US20060122188A1 (en) | 2006-06-08 |
| ATE477800T1 (de) | 2010-09-15 |
| CN1747732A (zh) | 2006-03-15 |
| OA12970A (en) | 2006-10-13 |
| NO20053335L (no) | 2005-09-07 |
| AP2005003363A0 (en) | 2005-09-30 |
| AU2003297763A1 (en) | 2004-06-30 |
| EA200500899A1 (ru) | 2006-02-24 |
| CA2507657C (en) | 2011-05-31 |
| RS20050450A (en) | 2007-08-03 |
| NZ540872A (en) | 2007-08-31 |
| ES2348942T3 (es) | 2010-12-17 |
| JP2006511519A (ja) | 2006-04-06 |
| JP4662777B2 (ja) | 2011-03-30 |
| KR20050085580A (ko) | 2005-08-29 |
| WO2004052366A9 (en) | 2005-06-23 |
| ZA200505492B (en) | 2006-03-29 |
| PL377053A1 (pl) | 2006-01-23 |
| ECSP055912A (es) | 2005-11-22 |
| DE60333866D1 (de) | 2010-09-30 |
| MXPA05006302A (es) | 2005-08-29 |
| US7084142B2 (en) | 2006-08-01 |
| EP1578423B1 (en) | 2010-08-18 |
| US7056923B2 (en) | 2006-06-06 |
| CA2507657A1 (en) | 2004-06-24 |
| US20040138229A1 (en) | 2004-07-15 |
| EP1578423A1 (en) | 2005-09-28 |
| UA83648C2 (ru) | 2008-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0317222A (pt) | Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas | |
| BR0307429A (pt) | Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3 | |
| BR0307409A (pt) | Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico | |
| BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso | |
| WO2002098856A3 (en) | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists | |
| BR0309106A (pt) | Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm | |
| BRPI0409680A (pt) | análogos de fosfonato anti-cáncer | |
| AR021844A1 (es) | Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion | |
| BR0015963A (pt) | Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos | |
| NO20055590L (no) | Kinaseinhiberende fosfonatanaloger | |
| HUP0500200A2 (hu) | Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények | |
| BRPI0316732B8 (pt) | composto derivado de 3-aminopirrolidina e sua composição farmacêutica | |
| NO20052496L (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
| BRPI0512352A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
| UY27986A1 (es) | Nuevas quinazolinonas espirocondensadas y su uso c omo inhibidores de la fosfodiesterasa | |
| UY29169A1 (es) | Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica | |
| BRPI0411414A (pt) | derivados de quinolil amida como antagonistas de cdr-5 | |
| DK1551803T3 (da) | Azabicycloderivater som muskarine receptorantagonister | |
| WO2005060959A8 (en) | Pyrazole derivatives and use thereof as orexin receptor antagonists | |
| YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
| BR0214140A (pt) | Derivados de piperidina e sua utilização como moduladores da atividade de receptor de quimiocina (especialmente ccr5) | |
| BRPI0411585A (pt) | compostos, composição farmacêutica e método de aglutinar receptores opióides em um paciente com necessidade dos mesmos | |
| BR0316355A (pt) | Derivados de imidazoquinolina como ligantes de receptores de adenosina a3 | |
| BR0214649A (pt) | Derivados de aminotetralina como antagonistas do receptor muscarìnico | |
| NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |